Chris De Jonghe

As fast-spreading viral diseases are a constant threat to the livestock industry, ViroVet’s team of researchers and unique network of academic and industrial partners will deliver products to reduce the impact of these diseases by providing innovative virus control solutions to secure and improve the health and value of livestock.

MyCartis is an immuno-diagnostic solution provider assuring accurate, clinical guidance with its sample to answer Evalution® platform. MyCartis develops its own immuno-diagnostic menu for the clinical user and collaborates with partners to port assays on its platform. EVALUTION® leverages high quality analytical performance from conventional immunodiagnostic approaches with the unique capability to quantify and monitor binding reactions in real-time. This provides the user with novel, timely and hence highly actionable information. MyCartis primarily focuses on oncology and in particular immuno-oncology. One of the assays in development will monitor adverse events in cancer patients undergoing immuno-oncology treatment. In addition to the existing Evalution® RUO platform, MyCartis is developing a CE-IVD clinical configuration and has obtained its ISO13485 certification. Visit www.mycartis.net or contact MyCartis for more information: info@mycartis.net

Confo Therapeutics’ unparalleled technology stabilizes functional conformations of GPCRs (G protein-coupled receptors) to uncover a wide range of previously inaccessible GPCRs as drug targets. This technology platform combined with the pharmacologic and biologic insight it provides, allows Confo to build a multi-indication pipeline of drug candidates with the potential to transform therapeutic outcomes for patients with severe illnesses lacking disease-modifying treatments. Confo Therapeutics was spun out of Vrije Universiteit Brussel (VUB) and VIB in 2015. Supported by international life-science focused investors and led by an experienced team of entrepreneurial professionals and scientists from successful biopharmaceutical companies, Confo Therapeutics benefits from the rich scientific and innovative ecosystem in Belgium. For more information: www.confotherapeutics.com

Celyad Oncology is a cutting-edge biotechnology company dedicated to pioneering the discovery and advancement of revolutionary technologies for chimeric antigen receptor (CAR) T-cells. Its primary objective is to unlock the potential of its proprietary technology platforms and intellectual property, enabling to be at the forefront of developing next-generation CAR T-cell therapies. By fully leveraging its innovative technology platforms, Celyad Oncology aims to maximize the transformative impact of its candidate CAR T-cell therapies and redefine the future of CAR T-cell treatments. Celyad Oncology is based in Mont-Saint-Guibert, Belgium. For more information, please visit www.celyad.com.

Vesalius Biocapital III is an European life sciences venture capital fund with EUR 120mio assets under management. We invest in European companies active in therapeutics development, medical devices & diagnostics and eHealth / mHealth.

eSATURNUS develops imaging technologies and multimedia solutions for operating rooms and hospitals. Video switching, medical data management and live surgery broadcast are the cornerstones of eSATURNUS. eSATURNUS offers two Medical Solutions: NUCLeUS™ – Smart Digital Operating Room. More info: http://www.esaturnus.com/products/nucleus NeBULA™ – Medical Video Acquisition and Archiving System. More info: http://www.esaturnus.com/products/nebula

VIB is a pioneering life sciences research institute where curiosity and collaboration drive bold, fundamental science. Since 1996, we have combined cutting-edge biomolecular research with a strong commitment to making a real impact on society. Our mission is clear: to expand scientific knowledge and improve people’s lives. At VIB, diverse and driven minds from multiple disciplines come together to explore the fundamental workings of life, human health, and disease. We believe that groundbreaking discoveries happen when people are given freedom, support, and trust to challenge themselves, and each other. 𝐖𝐞 𝐩𝐮𝐬𝐡 𝐬𝐜𝐢𝐞𝐧𝐜𝐞 𝐟𝐨𝐫𝐰𝐚𝐫𝐝. We conduct bold, curiosity-driven research to expand the frontiers of life sciences. 𝐖𝐞 𝐠𝐫𝐨𝐰 𝐛𝐲 𝐜𝐡𝐚𝐥𝐥𝐞𝐧𝐠𝐢𝐧𝐠 𝐨𝐮𝐫𝐬𝐞𝐥𝐯𝐞𝐬. VIB offers strong technical support, while encouraging ownership and ambition. Yes, the bar is high, but so is our motivation. We know what we’re striving for and why it matters. 𝐖𝐞 𝐰𝐨𝐫𝐤 𝐭𝐨𝐠𝐞𝐭𝐡𝐞𝐫 𝐭𝐨 𝐦𝐚𝐤𝐞 𝐚 𝐝𝐢𝐟𝐟𝐞𝐫𝐞𝐧𝐜𝐞. We share knowledge, value diversity and foster and inclusive culture. Our impact extends beyond the lab, we bring science to society. Rooted in close partnerships with five Flemish universities (Ghent, KU Leuven, Antwerp, VUB, and UHasselt) and backed by solid funding, VIB is a vibrant ecosystem where science and people thrive. Follow VIB for groundbreaking discoveries and career opportunities or join us to help shape the future of life sciences. 𝐅𝐨𝐫 𝐣𝐨𝐛 𝐨𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐢𝐞𝐬 > 𝐣𝐨𝐛𝐬.𝐯𝐢𝐛.𝐛𝐞

Flindr Therapeutics, based in Oss in the Netherlands, is a private pre-clinical biotech company developing next-generation precision oncology treatments. The Company, previously called Immagene, was spun out of the Netherlands Cancer Institute (NKI) and Oncode Institute in 2020, by founders Prof Daniel Peeper, Prof Christian Blank and Dr Maarten Ligtenberg. Flindr is actively building a pipeline of highly promising, first-in-class precision oncology therapies identified through the ImmunoGram Drug Discovery Engine. It is backed by V-Bio Ventures, Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders Future Tech Fund, Curie Capital, Oncode Oncology Bridge Fund, Swanbridge, Innovatiefonds Noord Holland, and BOM. Flindr has entered into a research collaboration with the NKI, and the VIB (Flanders Institute of Biotechnology).

reMYND NV is a dynamic biotech company located in Leuven (Belgium) that actively drives R&D in the field of protein misfolding diseases, among others Alzheimer’s disease (AD) and Parkinson’s disease (PD). The company consists of two independently managed units. The Drug Discovery and Development Unit focuses on disease-modifying treatments for among others AD and PD (counteracting TAU and aSyn toxicity, respectively). The Contract Research Unit offers extensive experience in the testing of experimental Alzheimer therapies in its unique and proprietary transgenic mouse models. For more information please visit www.remynd.com Alternatively, please contact Koen De Witte (Managing Director - pipeline@remynd.com) to hear more about reMYND's pipeline or Bart Roucourt (Manager Contact Research - cro@remynd.com) to get more information on reMYND's Contract Research Offering.